Desvenlafaxine Succinate
Product Images NDC 50090-4069

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 50090-4069). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Desvenlafaxine 01)

Chemical structure of desvenlafaxine succinate monohydrate, showing the molecular arrangement of atoms including a phenol group, hydroxyl groups, a dimethylamino side chain, cyclohexane ring, succinate, and a water molecule.*

FDA Label Image

Figure 1 (Desvenlafaxine 02)

A horizontal bar chart depicting the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC relative to reference values. The chart categorizes data by renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population description by gender and age groups (65-75 years, >75 years). Each category shows geometric mean ratios with error bars representing confidence intervals.*

FDA Label Image

Figure 2 (Desvenlafaxine 03)

A pharmacokinetic chart showing the geometric mean ratio with 90% confidence intervals for Cmax and AUC of Desvenlafaxine Succinate when exposed to the CYP3A4 inhibitor ketoconazole. The x-axis represents the change relative to reference values, ranging from 0.50 to 2.0.*

FDA Label Image

Figure 3 (Desvenlafaxine 04)

A scatter plot chart illustrating the geometric mean ratio (90% confidence interval) of drug interactions involving Desvenlafaxine at different dosages (50 mg, 100 mg, 400 mg) with interacting drugs Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The chart includes pharmacokinetic parameters Cmax, AUC, AUCinf, and Cmax with confidence intervals, showing changes relative to reference values for these interactions.*

FDA Label Image

Figure 4 (Desvenlafaxine 05)

A Kaplan-Meier curve graph depicting the estimated proportion of patients with relapse (%) over time to relapse (days from randomization). The graph compares Desvenlafaxine 50 mg (solid blue line) versus placebo (dashed red line) over approximately 180 days, showing lower relapse rates with Desvenlafaxine.*

FDA Label Image

Figure 5 (Desvenlafaxine 06)

A line chart comparing the estimated proportion of patients with relapse (%) over time (days from randomization) between Desvenlafaxine and Placebo. The x-axis represents time to relapse in days, ranging from 0 to 180, and the y-axis shows the percentage of patients with relapse from 0 to 50%. Desvenlafaxine is represented by a solid blue line, showing a slower increase in relapse proportion, while Placebo is depicted by a dashed red line with a steeper increase, indicating higher relapse rates over time.*

FDA Label Image

Logo (Desvenlafaxine 07)

FDA Label Image

Logo (Desvenlafaxine 08)

FDA Label Image

Label Image (Lbl500904069)

Desvenlafaxine Succinate 50 mg extended-release tablets by A-S Medication Solutions. The label shows a package size of 30 tablets, each with a desvenlafaxine succinate equivalent to 50 mg of desvenlafaxine. Storage instructions specify 68 to 77 degrees Fahrenheit. The label includes dose and package information along with lot and NDC numbers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.